Skip to content

CROI: Effects of transmitted drug resistance on viral load are drug class specific

CROI: Ugandan study confirms low CD4 count, low body weight, TB and anaemia major risk factors for death after starting ART

CROI: Anti-HBV drug entecavir also active against HIV and promotes antiretroviral resistance

CROI: Maraviroc shows potent effect in highly treatment-experienced

CROI: Microbicide failure poses more questions than answers

CROI: Kaletra less likely to cause fat loss than efavirenz when paired with NRTIs

CROI: Cotrimoxazole prophylaxis reduces risk of death by 41% during first six months of ART

CROI: Integrase inhibitor raltegravir (MK-0518) doubles HIV suppression in treatment-experienced patients at 16 weeks

CROI: Non-AIDS malignancies now more common than AIDS-defining cancers in people with HIV